Evolution of Bicuspid Valves at 12 Months

Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise. 

válvulas bicúspides

TAVR has seen significant advancements in the treatment of this disease. In some registries, its progression resembles that of tricuspid aortic valves (TAV). However, whether the different types of BAV have a similar evolution remains uncertain.

Researchers conducted an analysis on 1319 consecutive patients who underwent TAVR, of which 642 had TAV, 328 had BAV Type 0, and 302 had BAV Type I. 

The primary endpoint (PE) assessed was all-cause death and stroke at 30 days and one year.

Given the differences between the populations, propensity score matching was applied, resulting in 121 patients in each group. 

The average age was 73 years; 62% of patients were men, the STS score was 5.1%, 19% of subjects had diabetes, 45% of patients had chronic obstructive pulmonary disease (COPD), 34% had coronary artery disease, 18% had a history of stroke, and 15% had atrial fibrillation.

Read also: Use of IVUS in Complex PCI: Results according to Operator Experience.

In most cases, self-expanding valves were implanted. Hospital complications were similar between the groups. 

There were no significant differences in the PE between the groups (6% vs. 2% vs. 2% for BAV Type 0, Type I, and TAV).

The 30-day mortality rates were 4.2% vs. 1.7% vs. 1.7%, respectively, and the 1-year mortality rates were 10% vs. 2.3% vs. 6.2%. The incidence of stroke was 1% vs. 0.9% vs. 0% at 30 days and 1.4% vs. 1.6% vs. 1.3% at one year.

Read also: Retrograde Approach to Chronic Total Occlusions: Techniques and Outcomes According to the PROGRESS-CTO Registry.

The presence of a mean gradient ≥20 mmHg was more frequent in the BAV Type 0 group.

Conclusion

Major clinical events after TAVR in aortic stenosis patients with bicuspid aortic valve Type 0, Type I, and tricuspid aortic valve were equivalent in the short and medium term during follow-up. These observations suggest the need for future research in international prospective registries or randomized studies.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves.

Reference: Jingjing He, et al. Circ Cardiovasc Interv. 2023;16:e013083. DOI: 10.1161/CIRCINTERVENTIONS.123.013083.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...